Aptose Biosciences Inc. (APTO)
- Previous Close
1.2300 - Open
1.2600 - Bid 1.1600 x 100
- Ask 1.2700 x 100
- Day's Range
1.2000 - 1.2600 - 52 Week Range
0.3600 - 6.6000 - Volume
56,209 - Avg. Volume
93,519 - Market Cap (intraday)
19.244M - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-7.5800 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
www.aptose.comRecent News: APTO
Performance Overview: APTO
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APTO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APTO
Valuation Measures
Market Cap
18.93M
Enterprise Value
10.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.35
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.21
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-102.23%
Return on Equity (ttm)
-293.95%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-51.21M
Diluted EPS (ttm)
-7.5800
Balance Sheet and Cash Flow
Total Cash (mrq)
9.25M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-25.82M